Elicio Therapeutics, Inc. has announced its financial results for the third quarter of 2026, marking a pivotal moment for the company as it continues to develop innovative immunotherapies for cancer treatment. The results reflect both the company’s financial health and significant progress in its clinical trials, particularly the AMPLIFY-7P study targeting pancreatic cancer.

On November 5, 2026, Elicio reported a net loss of $8 million for the quarter ending September 30, 2026, an improvement from a net loss of $10.1 million during the same period in 2025. This reduction in losses is attributed to lower clinical trial costs as the company moves forward with its Phase 2 study of camupepimut, an investigational immunotherapy.

Background

Elicio Therapeutics, Inc. (Nasdaq: ELTX) is a clinical-stage biotechnology company based in Boston, Massachusetts, specializing in next-generation immunotherapies for KRAS-driven cancers. The company operates under the SIC classification of 2834, which pertains to pharmaceutical preparations. Elicio aims to leverage its proprietary Amphiphile (AMP) technology to develop effective off-the-shelf immunotherapies, particularly for pancreatic and colorectal cancers.

Recent filings from Elicio include a 10-Q and multiple 8-K forms, detailing various corporate updates and financial results. The latest filing, dated November 5, 2026, includes critical information about the company’s financial condition and operational results.

What the Filing Says

In the recent filing, Elicio highlighted key findings from its AMPLIFY-7P trial, stating, "The 49% lower risk of disease recurrence or death among patients with undetectable ctDNA at baseline... reinforces the encouraging clinical activity observed across both subgroups." These results are significant as they inform future patient stratification and dosing for upcoming Phase 3 studies.

The company also reported that its cash and cash equivalents stood at $30.9 million as of September 30, 2026, which is expected to support operations into the second quarter of 2027.

Impact

The findings from the AMPLIFY-7P trial may significantly influence treatment strategies for pancreatic ductal adenocarcinoma (PDAC), a particularly aggressive form of cancer. Elicio's advancements could impact patients with KRAS mutations, as well as healthcare providers and stakeholders in the pharmaceutical industry focusing on cancer therapies.

What's Next

Elicio is set to initiate a Phase 1 study evaluating camupepimut in combination with daraxonrasib, with or without nivolumab, in metastatic pancreatic cancer in the fourth quarter of 2026. This study aims to explore the potential of combining direct RAS inhibition with KRAS-specific immune activation, further advancing Elicio's innovative treatment approaches.

For further details, the full press release can be found in Exhibit 99.1 of the filing, available through the SEC’s website under accession number 0001601485-26-000065.